A Multiple Dose Study Investigating Pharmacodynamics and Pharmacokinetics of Subcutaneous NNC0363-1063 in Participants With Type 1 Diabetes
Latest Information Update: 05 Jan 2026
At a glance
- Drugs NNC 0363 1063 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 02 Jan 2026 Status changed from not yet recruiting to recruiting.
- 26 Dec 2025 Status changed from recruiting to not yet recruiting.
- 11 Dec 2025 New trial record